AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study

AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B